Product and intended use
Clarify who the product is for, where it is used, what decision it supports and what must be true for it to matter.
Medtech product development strategy
Define the product before the programme defines it for you.
Genvissa helps teams translate promising science and engineering into a medical product that is clear enough to design, evidence, regulate, manufacture, fund and adopt.
The core challenge
A prototype is not yet a product strategy.
Medtech programmes become expensive when fundamental choices remain implicit.
Teams can move quickly on engineering while the intended use, user, pathway, claims or evidence requirement remains unresolved. That creates rework, regulatory ambiguity and an investment story that does not connect spend to value.
Genvissa creates a controlled route through those choices, making assumptions visible and sequencing work around the decisions that genuinely change technical, clinical and commercial risk.
What we connect
Product development as one decision system.
Requirements and development
Translate the proposition into claims, product requirements, work packages, decision gates, partners, budgets and a realistic critical path.
Evidence and regulation
Align analytical, technical, clinical, usability, quality and regulatory needs so evidence is generated for the claims and markets that matter.
Manufacturing and supply
Bring design transfer, supplier capability, process controls, cost, quality and scale into the strategy before they become late-stage constraints.
Investment and milestones
Connect each major spend to a risk reduction, evidence point or value inflection that a board or investor can understand.
Workflow and market reality
Test how the product fits the real healthcare pathway, who benefits, who pays and what could block sustained use.
Target product profile
A decision-ready definition of intended use, users, setting, workflow, claims, performance, evidence and commercial constraints.
Integrated roadmap
A sequenced 12 to 24-month plan linking product, quality, regulatory, clinical, manufacturing and commercial work.
Claims-to-evidence matrix
A clear line from each intended claim to the technical, analytical, clinical and usability evidence required to support it.
Decision gates and budget
Defined assumptions, owners, acceptance criteria, risks and funding needs for each meaningful value inflection.
When to engage
Before the next expensive commitment.
This work is particularly useful before design freeze, external development spend, analytical or clinical studies, manufacturing transfer, a major grant application or investment round.
Can you support a university spinout or pre-company project?
Yes. The scope is kept proportionate, focusing on the few product, evidence, intellectual-property and funding decisions that determine whether a credible venture can be built.
Can you review a programme already in development?
Yes. A focused diagnostic can identify conflicting assumptions, missing evidence, weak controls and the recovery actions required before further capital is committed.
Do you replace regulatory or engineering specialists?
No. Genvissa integrates the critical path and brings in the right formal specialist competence where detailed engineering, clinical, legal, statistical or regulatory opinion is required.
Make the next decision count
Build the programme around a product that can succeed.
Start with the decision, evidence gap or development milestone that currently carries the most risk.